Impact BioMedical, Inc. ( (IBO) ) has shared an update.
On March 11, 2025, Impact BioMedical, Inc. appointed Mr. Chan Heng Fai Ambrose as a Director of the Company. Mr. Chan brings over forty-five years of experience in the financial and equity investment industry, having held significant positions in various companies across multiple sectors and countries. His extensive background in restructuring companies and leadership roles in publicly listed firms is expected to enhance the strategic direction and governance of Impact BioMedical, Inc.
More about Impact BioMedical, Inc.
YTD Price Performance: -56.88%
Average Trading Volume: 29,515
Technical Sentiment Consensus Rating: Strong Buy
Learn more about IBO stock on TipRanks’ Stock Analysis page.